Figure 2

Proportion of patients with hemoglobin concentration in various categories, C-reactive protein (CRP) levels, iron stores and usage before and after conversion to darbepoetin alfa Q2W. Most patients (73.0%) achieved a hemoglobin concentration >11 g/dL at month 12, which was similar to the proportion of patients 6 months prior to conversion (69.3%) and at conversion (76.2%). The proportion of patients achieving a hemoglobin concentration >11 and ≤13 g/dL was 52.5% 6 months prior to conversion, 43.7% at conversion, and 54.0% at month 12. CRP and iron levels were stable over the study. Between 43.2% and 46.6% of patients were on iron therapy in any 3-month period during the study. Of those patients on iron therapy, about 60% of patients were receiving oral iron therapy. Abbreviations: C, at conversion to darbepoetin alfa every 2 weeks; CRP, C-reactive protein; PO, oral; IV, intravenous; Q1-Q3, quartile ranges; TSAT, transferrin saturation.